[go: up one dir, main page]

WO2025185024A8 - Docetaxel adiposome formulation, preparationmethod therefor, and use thereof - Google Patents

Docetaxel adiposome formulation, preparationmethod therefor, and use thereof

Info

Publication number
WO2025185024A8
WO2025185024A8 PCT/CN2024/103795 CN2024103795W WO2025185024A8 WO 2025185024 A8 WO2025185024 A8 WO 2025185024A8 CN 2024103795 W CN2024103795 W CN 2024103795W WO 2025185024 A8 WO2025185024 A8 WO 2025185024A8
Authority
WO
WIPO (PCT)
Prior art keywords
docetaxel
adiposome
formulation
therefor
preparationmethod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2024/103795
Other languages
French (fr)
Chinese (zh)
Other versions
WO2025185024A1 (en
Inventor
曹震
潘斌
张高薪
李泽民
支泽仑
周畅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wecarelife Biotech Co Ltd
Original Assignee
Wecarelife Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wecarelife Biotech Co Ltd filed Critical Wecarelife Biotech Co Ltd
Publication of WO2025185024A1 publication Critical patent/WO2025185024A1/en
Publication of WO2025185024A8 publication Critical patent/WO2025185024A8/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are a docetaxel adiposome formulation, a preparation method therefor, and use thereof. The docetaxel adiposome formulation comprises a monomolecular phospholipid membrane and docetaxel and a neutral lipid that are wrapped in the monomolecular phospholipid membrane. Targeted modification is further carried out on the surface of the docetaxel adiposome. The adiposome formulation has good bioavailability and safety, and the anti-cancer effect of the formulation is significantly superior to that of a clinically used docetaxel injection.
PCT/CN2024/103795 2024-03-05 2024-07-05 Docetaxel liposome formulation, preparation method therefor, and use thereof Pending WO2025185024A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202410251160.7 2024-03-05
CN202410251160 2024-03-05

Publications (2)

Publication Number Publication Date
WO2025185024A1 WO2025185024A1 (en) 2025-09-12
WO2025185024A8 true WO2025185024A8 (en) 2025-11-27

Family

ID=96989878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2024/103795 Pending WO2025185024A1 (en) 2024-03-05 2024-07-05 Docetaxel liposome formulation, preparation method therefor, and use thereof

Country Status (1)

Country Link
WO (1) WO2025185024A1 (en)

Also Published As

Publication number Publication date
WO2025185024A1 (en) 2025-09-12

Similar Documents

Publication Publication Date Title
US12472219B2 (en) Encapsulated cannabinoid formulations for transdermal delivery
Gershkovich et al. A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery
WO2007011940A3 (en) Sustained release of antiinfectives
US11819486B2 (en) Composition for external use on skin for inflammatory diseases
Schaller et al. Interaction of liposomes with human skin: the role of the stratum corneum
KR100534511B1 (en) Composition with Azelaic Acid
Zakharova et al. Supramolecular strategy for the design of nanocarriers for drugs and natural bioactives: Current state of the art (a review)
Abdelalim et al. Oleosomes encapsulating sildenafil citrate as potential topical nanotherapy for palmar plantar erythrodysesthesia with high ex vivo permeation and deposition
WO2025185024A8 (en) Docetaxel adiposome formulation, preparationmethod therefor, and use thereof
Risaliti et al. Preparation and characterization of ascosome vesicles loaded with khellin
WO2008058366A1 (en) Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof
EP3568123B1 (en) Introduction of hardly soluble and/or watersoluble active agents with lipid based nanoparticles/nanovesicles into a hydrophilic threedimensional network of cellulose
WO2012109151A1 (en) Permeation enhancers with liposomes for topical formulations
KR100490365B1 (en) Cosmetics including nanovesicle
WO2023034957A8 (en) Stabilization of antigens for long term administration in transdermal microneedle patches
Nastruzzi et al. Use ano stability of liposomes in dermatological preparations
Zhu et al. Nanovesicles for transdermal drug delivery
KR101512190B1 (en) Amiderm composition for transdermal transfer
KR20000064684A (en) How to dissolve hydrophilic substances (eg proteins) in hydrophobic solvents
FR2924612A1 (en) Use of poppy petal (Papaver rhoeas) extract to prepare cosmetic and/or dermatological composition e.g. for the nutrition of dermal and epidermal cells, and restructuring and strengthening the dermal and epidermal layers of the skin
EP0372527A1 (en) Topical compositions containing diclofenac
WO2025185023A8 (en) Neogambogic acid adiposome, preparation method therefor, and use thereof
Gilani et al. QbD considerations for topical and transdermal product development
WO2009074239A1 (en) Pharmaceutical foams
KR20200020502A (en) Process for preparing nano-liposome using horse fat and nanodiamon, and compositions comprising the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24927957

Country of ref document: EP

Kind code of ref document: A1